share_log

Altamira Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Sofinnova Capital VII FCPR (“SC VII”) EIN:(0.88%),Sofinnova Partners SAS, a French corporation (“SP SAS”)(0.88%), etc.

SEC announcement ·  Feb 14, 2019 12:02
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more